3 Healthcare Stock Stories For Tuesday Portfolio Wellness

Transition Therapeutics (NASDAQ: TTHI): Closing price $3.10

The firm has announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the evaluation, TT-401, a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight. The study enrolled diabetic patients at five dosing levels and non-diabetic obese patients at one dose level, with all dosing cohorts receiving five doses over a five week period. At the end of the treatment period, TT-401-treated patients in the three highest dose groups saw statistically significant decreases in mean fasting plasma glucose relative to placebo.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TTHI

Vivus (NASDAQ: VVUS): Closing price $13.29

On Tuesday morning, Vivus said that Qsymia was added to MEDCO national formulary in a tier-3 position with a prior authorization. The co-pay is anticipated to be between $50 and $60. Analyst Marko Kozul at Leerink Swann said that the “announcement of a new reimbursement deal with MEDCO is potentially more important than the previous one inked with Express Scripts. The new MEDCO deal provides a pharmacy formulary benefit for up to 38 million new lives versus the late fourth quarter 2012 ESI deal that covered up to 26.3 million lives (64.3 million total). The impact of this news is to convert Qsymia (obesity) reimbursement from the non-covered to the covered position.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Raptor Pharmaceutical Corp. (NASDAQ:RPTP): Closing price $6.90

Raptor has been awarded approval in the United States for its drug Procysbi to treat a rare metabolic disorder that attacks the kidneys. The drug was previously known as RP103, and could bring sales of $77 million in 2015, according to the average of two analysts’ estimates compiled by Bloomberg. The firm said in a statement Tuesday that it will receive a $25 million payment from the investment firm HealthCare Royalty Partners for the approval. Procysbi treats nephropathic cystinosis, which affects roughly 3,000 people globally, including 500 in the United States, according to an FDA statement.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RPTP

Don’t Miss: Who Will Get High Off The Marijuana Gold Rush?